Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Vivoryon Therapeutics regains China rights to varoglutamstat from Simcere Pharmaceuticals
Licensing deal, small molecule, kidney disease, milestone payments - Read more

Charles River Laboratories, Ipsen collaborate to use virtual control groups in toxicology studies
Research collaboration, toxicology, drug discovery, animal testing reduction, rare disease, oncology - Read more

Evommune licenses Hinova Pharmaceuticals' VAV1 molecular glue degrader for autoimmune diseases, $30M upfront, $1.1B milestones
Licensing deal, autoimmune, small molecule, milestone payments, royalties - Read more

UCB, Cradle partner to integrate AI platform across antibody discovery and lead optimisation
Research collaboration, antibody, AI/ML, drug discovery, lead optimization - Read more

MetaVia's DA-1726 (GLP-1/glucagon receptor agonist) cuts liver fat 68% in Ph1, targets alcohol-associated liver disease in Ph2
Small molecule, metabolic, GLP-1/glucagon receptor agonist, liver disease, alcohol-associated liver disease, obesity - Read more

Cloudbreak Pharma's CBT-001 (multi-kinase inhibitor) meets Ph3 endpoints for pterygium conjunctival overgrowth eye condition
Small molecule, ophthalmology, multi-kinase inhibitor, pterygium, eye drop - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Revolution Medicines' Rasonque posts $198M in Q3, hailed as best oncology drug launch in history
Small molecule, oncology, revenue impact, competitive - Read more

Rezera plans $181M IPO to fund phase 3 trial of NLRP3 inhibitor ruvonoflast
Cardiovascular, small molecule, anti-inflammatory, clinical-stage - Read more

T-Therapeutics raises $133M Series B to advance bispecific cancer and autoimmune drugs
Bispecific antibody, oncology, autoimmune, T cell engager, preclinical - Read more

Alethio Therapeutics raises $90M Series A to advance rare blood cancer treatments
Rare disease, hematology, antibody, preclinical, myeloproliferative neoplasms - Read more

bit.bio raises $25M Series D to expand human cell type portfolio and market access
Cell therapy, platform technology, drug discovery, neurological, opti-ox - Read more

Biograil raises €20M ($22.4M) in funding to advance oral drug delivery device toward Phase 1 trials
Oral drug delivery, platform technology, biologics, preclinical - Read more

Emvena Therapeutics receives undisclosed Seed investment to advance placenta-targeted mRNA medicines
mRNA therapeutics, lipid nanoparticle, maternal health, preclinical, rare disease - Read more

ANI Pharmaceuticals to acquire Egetis Therapeutics for $560M, boosting rare thyroid hormone disorder drug Emcitate
Small molecule, rare disease, major transaction, strategic - Read more

AstraZeneca reportedly offers $10B to acquire Rhythm Pharmaceuticals, targeting rare obesity drug Imcivree
Small molecule, rare disease, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

VintaBio assets auctioned amid CGT viral vector slowdown, including $17M Philadelphia facility and IP
Asset sale, cell and gene therapy, viral vector, manufacturing, CDMO - Read more

Agios Pharmaceuticals cuts 100+ R&D roles ahead of FDA sickle cell disease approval decision
Small molecule, rare disease, cost reduction, operational - Read more

FDA flags Vanda Pharmaceuticals' Nereus TV ad for misleading safety and effectiveness claims
Small molecule, motion sickness, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here